Induced pluripotent stem cells (iPSCs) are a type of stem cell that can be generated from adult cells through the process of cellular reprogramming. This involves the introduction of specific genes into the adult cells, which causes them to revert to a pluripotent state, similar to that of embryonic stem cells. Pluripotent stem cells have the ability to differentiate into any cell type in the body.

iPSCs were first produced in 2006 and have since been generated from a variety of cell types, including skin cells, blood cells, and fat cells. After isolation and growth of the fibroblasts, our scientists will perform our mRNA reprogramming protocol for the generation of induced pluripotent stem cells.

iPSCs have been studied for a variety of potential therapeutic applications, including tissue repair and regeneration, and have shown promise in early clinical trials for a range of indications.

Induced pluripotent stem cells (iPSCs) have the potential to be used in a variety of biomedical applications, including:

Tissue repair and regeneration: iPSCs have the ability to differentiate into any cell type in the body and may be used to repair or regenerate damaged tissues. For example, iPSCs have been used to generate insulin-producing cells for the treatment of diabetes, and to generate neurons for the treatment of neurodegenerative diseases such as Parkinson's disease.

Drug development: iPSCs can be used to model diseases in the laboratory, allowing researchers to study the effects of drugs on specific cell types and to identify potential new therapies.

Personalized medicine: iPSCs can be generated from a patient's own cells, allowing for the production of patient-specific cells for use in cell-based therapies. This may reduce the risk of rejection and the need for immunosuppressive drugs.